The Egyptian Drug Authority (EDA) has announced the completion of the specialized training program on pharmacovigilance systems within pharmaceutical companies, with the participation of several pharmacovigilance representatives and quality officers, as part of efforts to enhance staff capabilities and improve the efficiency of the pharmacovigilance system.

The training program aims to qualify and empower pharmacovigilance representatives in pharmaceutical companies by ensuring their full understanding of pharmacovigilance system requirements and practical methods for their evaluation. It also included an explanation of the mechanisms for preparing pharmacovigilance system master files submitted to the EDA, as well as the standards that must be met to ensure their acceptance.

The program further addressed the most common observations that may lead to the rejection of submitted files, thereby contributing to improving the quality of pharmacovigilance systems within companies.

This comes within the EDA’s commitment to enhancing the competencies of personnel working in pharmacovigilance, keeping pace with global and local developments, and ensuring the optimal implementation of good pharmacovigilance practices, in a manner that supports patient safety and ensures the availability of safe and effective medicines.